Sunday - May 4, 2025
CARMEL, Ind., Nov. 9, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions, today announced that it expects to report third quarter 2023 financial results for the period ended September 30, 2023, on November 14, 2023. The Company has scheduled a conference call on the same day, at 9:00 AM ET, to discuss the results.
Interested parties can access the conference call via Internet webcast, which is available in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations or at https://app.webinar.net/QnrqX7vAKVL.
Investors who would like to submit a question to be addressed on the call should email the question to shamsian@lythampartners.com.
A webcast replay will be available in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations.
ABOUT SYRA HEALTH CORP.
Syra Health is a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions. Syra Health specializes in behavioral and mental health, digital health, and population health. Syra Health's solutions are centered on prevention, improved access, and affordable care. For more information, please visit www.syrahealth.com.
For more information, please contact:
Media:
Syra Health
Communications & Marketing Director
Christine Drury
317-385-9227
christined@syrahealth.com
Investors:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
shamsian@lythampartners.com
Last Trade: | US$0.09 |
Daily Change: | -0.01 -13.71 |
Daily Volume: | 200 |
Market Cap: | US$807K |
February 18, 2025 December 02, 2024 November 26, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load